Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 73-78 , May 2010

The upgraded role of HER3 and HER4 receptors in breast cancer

  • Angelos K. Koutras

      Affiliations

    • Division of Oncology, Department of Medicine, University Hospital of Patras, Rion, Greece
    • Corresponding Author InformationCorresponding author at: Division of Oncology, Department of Medicine, University Hospital, Patras Medical School, Rion 26504, Greece. Tel.: +30 2610999535; fax: +30 2610994645.
    • ,
  • George Fountzilas

      Affiliations

    • Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    • ,
  • Konstantine T. Kalogeras

      Affiliations

    • Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    • Hellenic Cooperative Oncology Group, Data Office, Athens, Greece
    • ,
  • Ioannis Starakis

      Affiliations

    • Division of Oncology, Department of Medicine, University Hospital of Patras, Rion, Greece
    • ,
  • Gregoris Iconomou

      Affiliations

    • Division of Oncology, Department of Medicine, University Hospital of Patras, Rion, Greece
    • ,
  • Haralabos P. Kalofonos

      Affiliations

    • Division of Oncology, Department of Medicine, University Hospital of Patras, Rion, Greece

,Accepted 29 April 2009.

References 

  1. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res. 2003;284:2–13
  2. Mosesson Y, Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol. 2004;14:262–270
  3. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–187
  4. Karamouzis MV, Badra FA, Papavassiliou AG. Breast cancer: The upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol. 2007;39:851–856
  5. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 1994;13:2831–2841
  6. Soltoff SP, Carraway KL, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994;14:3550–3558
  7. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell. 2007;12:104–107
  8. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 2008;13:215–223
  9. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;284:54–65
  10. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 2003;100:8933–8938
  11. Naidu R, Yadav M, Nair S, Kutty MK. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer. 1998;78:1385–1390
  12. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer. 2003;106:758–765
  13. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290–297
  14. Sassen A, Rochon J, Wild PJ, et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3, and HER4 in 278 breast cancer patients. Breast Cancer Res. 2008;10:R2;[Epub 2008 Jan 8]
  15. Lemoine NR, Barnes DM, Hollywood DP, et al. Expression of the ERBB3 gene product in breast cancer. Br J Cancer. 1992;66:1116–1121
  16. Gasparini G, Gullick WJ, Maluta S, et al. C-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma. An immunocytochemical study. Eur J Cancer. 1994;30A:16–22
  17. Quinn CM, Ostrowski JL, Lane SA, Loney DP, Teasdale J, Benson FA. C-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology. 1994;25:247–252
  18. Travis A, Pinder SE, Robertson JFR, et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer. 1996;74:229–233
  19. Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res. 2000;6:4217–4225
  20. Lee Y, Cho S, Seo JH, et al. Correlated expression of erbB-3 with hormone receptor expression and favourable clinical outcome in invasive ductal carcinomas of the breast. Am J Clin Pathol. 2007;128:1041–1049
  21. Koutras AK, Kalogeras KT, Dimopoulos M-A, et al. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer. Br J Cancer. 2008;99:1775–1785[Epub 2008 Nov 4]
  22. Lee H, Akita RW, Sliwkowski MX, Maihle NJ. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res. 2001;61:4467–4473
  23. Offterdinger M, Schöfer C, Weipoltshammer K, Grunt TW. c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol. 2002;157:929–939
  24. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer. 2007;120:1874–1882
  25. Petrelli F, Cabiddu M, Cazzaniga ME, Cremonesi M, Barni S. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist. 2008;13:373–381
  26. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437–441
  27. Menendez JA, Lupu R. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?. Breast Cancer Res. 2007;9:111
  28. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007;97:453–457
  29. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, Bacus SS. The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer. 2004;91:1190–1194
  30. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res. 2009;69:2191–2194[Epub 2009 Mar 10]
  31. Sartor CI, Zhou H, Kozlowska E, et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol. 2001;21:4265–4275
  32. Naresh A, Long W, Vidal GA, et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006;66:6412–6420
  33. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER-4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res. 2005;11:2163–2168
  34. Kainulainen V, Sundvall M, Määttä JA, Santiestevan E, Klagsbrun M, Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem. 2000;275:8641–8649
  35. Rio C, Buxbaum JD, Peschon JJ, Corfas G. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem. 2000;275:10379–10387
  36. Ni CY, Murphy MP, Golde TE, Carpenter G. Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001;294:2179–2181
  37. Jones FE. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia. 2008;13:247–258
  38. Zhu Y, Sullivan LL, Nair SS, et al. Coregulation of estrogen receptor by estrogen-inducible ERBB4/HER4 establishes a growth promoting autocrine signal in breast cancer. Cancer Res. 2006;66:7991–7998
  39. Knowlden JM, Gee JM, Seery LT, et al. c-erbB-3 and c-erbB-4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene. 1998;17:1949–1957
  40. Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res. 1999;59:5315–5322
  41. Kew TY, Bell JA, Pinder SE, et al. C-erbB-4 protein expression in human breast cancer. Br J Cancer. 2000;82:1163–1170
  42. Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas. C-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol. 2002;196:17–25
  43. Zaczek A, Wełnicka-Jaśkiewicz M, Bielawski KP, et al. Gene copy numbers of HER family in breast cancer. J Cancer Res Clin Oncol. 2008;134:271–279
  44. Aubele M, Auer G, Walch AK, et al. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer. 2007;96:801–807
  45. Junttila TT, Sundvall M, Lundin M, et al. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res. 2005;65:1384–1393
  46. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res. 2008;68:6387–6395
  47. Koutras AK, Evans TRJ. The epidermal growth factor receptor family in breast cancer. OncoTargets Ther. 2008;1:5–19
  48. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol. 1998;185:236–245
  49. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat. 1999;53:167–176

PII: S1040-8428(09)00102-4

doi: 10.1016/j.critrevonc.2009.04.011

Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 73-78 , May 2010

Article Tools